IntelGenx Technologies Corp (IGXT)

[92662]

Lilly's Alzheimer's drug.
"We have treated mice with a new type of drug, and found that these drugs can not only improve symptoms of brain degeneration, such as cognitive decline, but can also extend the life-span of these terminally-sick mice. Our study opens up avenues for researchers to look at new drugs that treat the symptoms of Alzheimer's and also slow disease progression"- Professor Andrew Tobin
An international team of scientists has announced a new advance in the fight against Alzheimer's disease by identifying a new drug target for not only improving symptoms of brain degeneration - but also to extend the life-span of the terminally ill mice.
The four-year study by Medical Research Council (MRC) scientists based at the MRC Toxicology Unit at the University of Leicester is published in the Journal of Clinical Investigation. The study was led by Professor Andrew Tobin alongside colleagues from pharmaceutical company Eli Lilly and Company and the Monash Institute for Pharmaceutical Sciences in Australia. The project was also partly supported by the Welcome Trust.